Review of: "Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review"

A review of psilocybin as a treatment for alcohol use disorder (AUD) examines the history, mechanisms, and clinical evidence for psychedelic-assisted therapy. The authors argue that psilocybin, when combined with psychotherapy, may help reduce alcohol consumption and support abstinence by disrupting maladaptive neural patterns and enhancing psychological insight. The text notes that psilocybin at 25 mg/70 kg produces robust psychedelic effects, contrary to a claim that it does not. Adverse effects are discussed, but the review does not present original data. The authors suggest psilocybin shows promise for AUD but emphasize the need for further controlled trials.

Study at a glance

Abstract

Things to consider: .In the intro: "The so-called magic mushrooms from which psychedelics are extracted were traditionally absorbed by South-American peoples." This is clunky and I suspect it is due to translation errors; consider changing it. .In the intro: "In 1998, Dr. Heffter nally discovered a psychedelic active substance and named it mescaline." This was rst published in 1897, not 1998. .Consider describing why psychedelics weren't studied again until 1990, due to the Federal Controlled Substances Act of 1970, which was for DMT-not psilocybin. .Materials and methods -"biodisponsibility". .Same section -unclear why much of this was included. .Data sources section -psilocybin for the cure of AUD.I don't think "cure" is the word you are looking for. .There are concerns between my numbers #6 and #8, but I did not delve into them at this time. .Section 3.3 Adverse effects; "So far, it is reasonable to conclude that psilocybin does not induce psychedelic effects at clinically tested doses (25mg/70kg)." This is not accurate.and dangerous, leading people to believe that this is a low dose.as this is the dose that produces robust psychedelic effects.See -https://www.technologynetworks.com/neuroscience/news/psilocybin-is-safe